Skip to content

Circles

S

Supernus Pharmaceuticals, Inc.

SUPN· Nasdaq

S

SUPNSupernus Pharmaceuticals, Inc.

SUPNSupernus Pharmaceuticals, Inc.·Earnings record

Q1 2011

Source filing unavailable

Next · Q2 2011

Q1 2011 · —

Revenue—

Net Income

-$11.05M

no prior Q1 2010 on file

EPS Diluted

-$6.64

no prior Q1 2010 on file

Operating Income-$9,198,000—

Operating Cash Flow-$9,801,000—

Free Cash Flowderived-$10,004,000—

Same quarter

no prior Q1 2010 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q1 ’11Q2 ’11 Q3 ’11 Q4 ’11 Q1 ’12 Q2 ’12 Q3 ’12 Q4 ’12 Q1 ’13…

Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy